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higher probability of parental productivity losses (OR = 4.7;
95%IC 2.3–9.7, p < 0.001) parental job switching (OR = 4.8;
95%IC 1.2–19.4, p = 0.006) and need of a dedicated caregiver
(OR = 3.3; 95%IC 1.7–6.4, p = 0.006). The average yearly man-
agement cost of ADHD vs. controls is respectively €1404 vs.
€896 in the perspective of the NHS; €1485 vs. €509 in the family
perspective; and €5287 vs. €1671 in the societal perspective.
Main cost drivers are hospitalisations, parental work-loss and
remedial teacher. ADHD mostly impacts QoL in the ‘Risk avoid-
ance’ and ‘Achievement’ domains. CONCLUSIONS: ADHD is
a social disease whose effects and burden in terms of cost and
QoL impact are mostly borne by the society and the families.
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OBJECTIVES: To estimate the costs of ADHD to society and the
health related quality of life (HRQoL) of children suffering from
ADHD. METHODS: A group of 70 children sufferering from
ADHD treated by a pediatrician was selected. For comparison a
group 60 of children having no behaviour problems was selected
from a survey (n = 3000 aged 6–8 years). HRQoL was assessed
by using the parent form of the Child Health Questionnaire
(CHQ-PF50). Health care utilisation of the children and the
mothers as well as productivity losses of the mothers were mea-
sured at baseline after 6, 12 and 18 months by using the Trimbos
and iMTA questionnaire on Cost associated with Psychiatric
illness’ (TiC-P). RESULTS: We found no differences between
mean scores of physical health between the ADHD patients and
the control group. The mean scores for psychosocial functioning
were signiﬁcant worse for the ADHD patients (p < 0.000). Direct
medical costs were signiﬁcantly higher for the ADHD patients
compared to the controls. Furthermore, mean direct medical
costs of the mothers of the ADHD patients were signiﬁcantly
higher. No differences were found in the costs of productivity
losses of the mothers. CONCLUSIONS: Children suffering from
ADHD have worse HRQoL. Furthermore, the medical costs of
the ADHD patients as well as of their mothers were signiﬁcantly
higher than for the controls.
PMH9
STIMULANT MEDICATION TREATMENT OF ATTENTION-
DEFICIT/ HYPERACTIVITY DISORDER IS ASSOCIATED WITH
DECREASED EMERGENCY DEPARTMENT COSTS AND
UTILIZATION: POPULATION-BASED STUDY
Katusic SK1, Barbaresi WJ1, Colligan RC1, Kemner J2,Weaver AL1,
Leibson CL1
1Mayo Clinic College of Medicine, Rochester, MN, USA; 2McNeil
Consumer & Specialty Pharmaceuticals, Fort Washington, PA, USA
OBJECTIVE: The association between treatment with stimulant
medication and medical utilization/costs among youth with
AD/HD is controversial. METHODS: We identiﬁed all individ-
uals born between January 1, 1976 and December 31, 1982 in
Rochester, MN, who met research criteria for AD/HD between
age ﬁve years and emigration from the area. Research identiﬁed
AD/HD cases were deﬁned by a model using a combination of
three categories of information (DSM-IV criteria, questionnaire
results, and clinical diagnoses). The 313 who resided locally
through age 17 years were followed for medication use, ED
visits, ED costs, and medical costs from January 1, 1987 to 18th
birthday or date last reviewed (mean follow-up = 10.2 + 1.4
years). RESULTS: The 231 youth treated with stimulants (74%)
were similar to the 82 untreated with respect to median annual
rates for ED visits (0.5 vs. 0.5), ED costs ($72 vs. $82), and total
medical costs ($661 vs. $741) (P > 0.05). Among the 231 treated
youth, duration of treatment ranged from 14 days to 11.8 years.
For analyzing the association between duration and outcomes,
the 82 youth with no treatment were assigned a duration of zero.
Duration of treatment (adjusted for age, sex, and psychiatric co-
morbidity) was associated with fewer ED visits (P = 0.02) but
higher total medical costs (P < 0.001). The 231 who were treated
experienced 853 periods of on vs. off treatment. On-treatment
periods (adjusted for age, sex, and calendar year) were associ-
ated with lower ED visits and ED costs (P < 0.02) and moder-
ately higher total medical costs (P < 0.001). CONCLUSION:
Findings refute previous suggestions that, among youth with
AD/HD, stimulant treatment is associated with two- to ﬁve-fold
increases in ED and total medical costs.
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OBJECTIVES: To estimate the cost-effectiveness of atomoxetine,
a new non-stimulant alternative for the treatment of childhood
ADHD, compared to current medications. METHODS: A
Markov model was developed to estimate the incremental cost
per quality-adjusted life year (QALY) gained by atomoxetine
compared to current practice for three patient populations: stim-
ulant-naïve (population-1); methylphenidate failure (population-
2) and; stimulant-incompatible (population-3). In each
population, algorithms were constructed to include either imme-
diate/extended-release methylphenidate (IR- or XR-MPH) as
ﬁrst-line alternative where appropriate, followed by ‘off-label’
dexamphetamine (IR-DEX) where appropriate, followed by ‘off-
label’ tricyclic antidepressants (TCA), then no medication. The
Markov process incorporated twenty-two health states, repre-
senting the range of outcomes across all modeled treatment
options. Utility values were derived from a survey of 83 parents
of ADHD children. The effectiveness and safety aspects of all
treatment options, based on a thorough review of controlled clin-
ical trials and other clinical literature, were validated by clinical
experts. Costs and outcomes were calculated over one year, with
costs (both direct and indirect) estimated from the Dutch soci-
etal perspective. RESULTS: For population-1, atomoxetine was
associated with additional costs of €495 and €448 per patient
compared to IR-MPH and XR-MPH, respectively. The addi-
tional QALYs gained were 0.026 and 0.020 per patient, respec-
tively. The incremental cost per QALY gained (ICER) with
atomoxetine compared to IR-MPH as ﬁrst-line alternative was
€18,831, and €22,804 compared to XR-MPH. The ICER was
€13,120 compared to IR-DEX in population-2. In population-3,
atomoxetine dominated TCA. Sensitivity analysis showed results
of the model to be robust to changes in most important vari-
ables, with the utility values being important indicators of the
cost-effectiveness of atomoxetine. CONCLUSIONS: The incre-
mental cost per QALY gained of atomoxetine compared to
current treatment options calculated in this analysis suggests that
atomoxetine offers good value-for-money in the treatment of
children with ADHD in The Netherlands.
